FDA Alerts

FDA approves Saphnelo for moderate to severe systemic lupus erythematosus

The U.S. Food and Drug Administration has approved anifrolumab-fnia (Saphnelo; AstraZeneca), a first-in-class type I interferon receptor antagonist for adults with moderate to severe systemic lupus erythematosus (SLE), according to a press release. This is the first new treatment for SLE in more than 10 years. Approval was based on...